I-Mab - ADR

NASDAQ:IMAB   3:59:55 PM EDT
67.29
+0.29 (+0.43%)
Products, Regulatory

I-Mab Reports Multiple Positive Clinical Updates Of Differentiated CD47 Antibody Lemzoparlimab

Published: 09/30/2021 12:38 GMT
I-Mab - ADR (IMAB) - I-mab Reports Multiple Positive Clinical Updates of Differentiated Cd47 Antibody Lemzoparlimab.
I-mab - Preliminary Efficacy and Safety Data From Phase 2 U.S. Trial in Nhl Has Been Submitted for Presentation at Ash 2021.
I-mab - On-going Clinical Trial of Lemzoparlimab in Combination With Aza for Aml/mds is on Track for Completion of Patient Enrollment by Q4 2021.
I-mab - Patient Enrollment for Trial is Expected to Be Completed in a Few Months.
I-mab - Plans to Initiate Another Registrational Trial in Patients With Mds in 2022 in China Based on Efficacy and Safety Data From Study.